| (Values in U.S. Thousands) | Oct, 2021 | Oct, 2020 | Oct, 2019 | Oct, 2018 | Oct, 2017 |
| Sales | 13,557 | 7,470 | 6,577 | 4,382 | 1,277 |
| Sales Growth | +81.49% | +13.58% | +50.10% | +242.99% | unch |
| Net Income | -14,233 | -4,761 | -3,615 | -2,437 | -3,619 |
| Net Income Growth | -198.95% | -31.70% | -48.34% | +32.66% | unch |
Valeo Pharmainc (VPH.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its products include Benztropine, Synacthen, M-Eslon, and among others.
Fiscal Year End Date: 10/31